Human heart cytosolic reductases and anthracycline cardiotoxicity

IUBMB Life

Volumn 52, Issue 1-2, 2001, Pages 83-88

  Mordente, A ^a   Meucci, E ^a   Martorana, G E ^a   Giardina, B ^a   Minotti, G ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Anthracyclines; Cardioprotection; Cardiotoxicity; Chalcones; Chemotherapy; Cytosolic reductases; Short chain coenzyme Q analogs

Indexed keywords

ACONITATE HYDRATASE; ALCOHOL; ANTHRACYCLINE DERIVATIVE; CHALCONE; DRUG METABOLITE; FREE RADICAL; HYDROXYL GROUP; IRON; OXIDOREDUCTASE; SABARUBICIN;

CARDIOMYOPATHY; CARDIOTOXICITY; CATALYSIS; CONFERENCE PAPER; CYTOSOL; ENZYME INHIBITION; HEART PROTECTION; HUMAN; HYPOTHESIS; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; STRUCTURE ACTIVITY RELATION;

ANTHRACYCLINES; CYTOSOL; DOXORUBICIN; FREE RADICALS; HEART; HUMANS; IRON; MODELS, BIOLOGICAL; MYOCARDIUM; OXIDOREDUCTASES;

EID: 0036137430     PISSN: 15216543     EISSN: None     Source Type: Journal    
DOI: 10.1080/15216540252774829     Document Type: Conference Paper

References (40)

1. Anthracyclines in the treatment of cancer. An overview
2. Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer
3. Clinical importance of anthracyclines in the treatment of acute myeloid leukemia
4. Adriamycin: Protection from cell death by removal of extracellular drug
5. Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase
6. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin
7. Doxorubicin-induced Id2A gene transcription is targeted at an activating transcription factor/cyclic AMP response element motif through novel mechanisms involving protein kinases distinct from protein kinase C and protein kinase A
8. Apoptotic events in a human ovarian cancer cell line exposed to anthracyclines
9. Adriamycin cardiomyopathy: Pathophysiology and prevention
10. Role of iron in anthracycline cardiotoxicity: New tunes for an old song?
11. Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction
12. The anthracyclines: Will we ever find a better doxorubicin?
13. Free radical formation by antitumor quinones
14. The role of iron in oxygen-mediated toxicities
15. Ferritin: Structure, function, and regulation
16. Sources and role of iron in lipid peroxidation
17. Doxorubicin cardio-toxicity: Analysis of prevailing hypotheses
18. Adriamycin-induced free radical formation in the perfused rat heart: Implications for cardiotoxicity
19. Acute adriamycin cardiotoxicity in rats
20. Paradoxical inhibition of cardiac lipid peroxidation in cancer patients treated with doxorubicin
21. Clinical and pharmacologic investigation of the effects of α-tocopherol on adriamycin cardiotoxicity
22. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine
23. Tissue distribution of doxorubicin and doxorubicinol in rats receiving multiple doses of doxorubicin
24. Genomic sequence and expression of a cloned human carbonyl reductase gene with daunorubicin reductase activity
25. The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 in cytosolic fractions from human myocardium
26. The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps: A correlative study of cardiac muscle with isolated membrane fractions
27. Doxorubicin cardiotoxicity may be due to its metabolite, doxorubicinol
28. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice
29. Aldose reductase induction: A novel response to oxidative stress of smooth muscle cells
30. Carbonyl reductase
31. Molecular and structural aspects of xenobiotic carbonyl metabolizing enzymes. Role of reductases and dehydrogenases in xenobiotic phase I reactions
32. Adriamycin and daunorubicin disposition in the rabbit
33. Inhibition of aldo-keto reductases by phenobarbital alters metabolism, pharmacokinetics and toxicity of doxorubicin in rats
34. Cardiomyopathy and other chronic toxic effects induced in rabbits by doxorubicin and possible prevention by coenzyme Q10
35. Cytosolic NADPH-UQ reductase, the enzyme responsible for cellular ubiquinone redox cycle as an endogenous antioxidant in the rat liver
36. The interaction of Q analogs, particularly hydroxydecyl benzoquinone (idebenone), with the respiratory complexes of heart mitochondria
37. A common ancestor for a subunit in the mitochondrial proton-translocating NADH:ubiquinone oxidoreductase (complex I) and short-chain dehydrogenases/reductases
38. A new nomenclature for the aldo-keto reductase superfamily
39. Molecular mechanisms of doxorubicin-induced cardiomyopathy. Selective suppression of Reiske iron-sulfur protein, ADP/ATP translocase, and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes
40. Anthracycline metabolism and toxicity in human myocardium: Comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metabolite